Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors
The purpose of this study is to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of Mogamulizumab and Nivolumab in subjects with locally advanced or metastatic solid tumors.
Solid Tumor
BIOLOGICAL: Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)
Number of subjects reporting adverse events, From the first dose of study medications until 90 days after the last dose of study medication|Number of subjects reporting serious adverse events, From the first dose of study medications until 90 days after the last dose of study medication|Percentage of subjects reporting serious adverse events, From the first dose of study medications until 90 days after the last dose of study medication|Percentage of subjects reporting adverse events, From the first dose of study medications until 90 days after the last dose of study medication|Number of subjects experiencing dose-limiting toxicity, For 28 days from the first dose of study medications
The purpose of this study is to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of Mogamulizumab and Nivolumab in subjects with locally advanced or metastatic solid tumors.